Description
Anti-CD248 FcγRIIB Binding Enhanced Antibody achieved by modifying the Fc of the antibody to increase the affinity of the antibody with FcγRIIb.
Applications
Enhancing primate/human antigen eliminating
Technology
FcγRIIB selective binding technology
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CD248 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD248 Molecule
Background
Ontuxizumab; 946415-62-9; MORAb-004; CD248; CD248 molecule; endosialin; CD164 sialomucin like 1; CD164L1; CD248 antigen; endosialin; endosialin; TEM1; tumor endothelial marker 1; 2610111G01Rik; CD164 sialomucin-like 1; CD248 antigen; endosialin; CD164L1; MGC119478;
Antibody Clone
AES-0622-ZP516
Description
Anti-CD248 FcγRIIB Binding Enhanced Antibody achieved by modifying the Fc of the antibody to increase the affinity of the antibody with FcγRIIb.
